SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SC-291’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SC-291 is under development for the treatment of acute lymphoblastic leukemia (ALL), relapsed/refractory large B-cell lymphoma including diffuse large cell lymphoma and relapsed/refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma (NHL), primary mediastinal large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma and autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The drug candidate comprises of allogeneic T cells which are genetically engineered to express the chimeric antigen receptor (CAR) targets cells expressing CD19. It is being developed based on hypoimmune technology. It is administered through intravenous route.
Sana Biotechnology overview
Sana Biotechnology is into the engraftment, manufacturing and commercialization of engineered cells as medicines to treat genetic disorders, central nervous system, cardiovascular, and oncology indications. The company is investigating drugs against non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, liver-related genetic disorders, hemoglobinopathies, diabetes, heart failure, Huntington’s, pelizaeus-merzbacher disease, secondary progressive multiple sclerosis, and heart diseases. It utilizes the Fusogen technology platform for in vivo cell engineering; and hyperimmune platform technology for ex vivo cell engineering. Sana Biotechnology works in collaboration with academic laboratories for harnessing their technologies and develop gene and cell therapies. It has operations in Cambridge and South San Francisco, the US. Sana Biotechnology is headquartered in Seattle, Washington, the US.
For a complete picture of SC-291’s drug-specific PTSR and LoA scores, buy the report here.